Results 231 to 240 of about 493,409 (267)
Some of the next articles are maybe not open access.
Combined modality therapy in the treatment of gynecologic malignancies
Seminars in Oncology, 2003During the last several years, combined modality therapy has become increasingly important in the treatment of several malignancies. This trend holds true in the treatment of the gynecologic malignancies. In this review we examine the evolving role of combined modality therapy in the treatment of patients with cervical, vulvar, endometrial, and ovarian
Mark A. Engleman, William Small
openaire +3 more sources
The Role of Gemcitabine in Combined Modality Therapy
2003Gemcitabine is a novel pyrimidine nucleoside analog with a broad spectrum of clinical antitumor activity. In addition to its initial approved indication in pancreatic carcinoma, gemcitabine has been licensed for the treatment of nonsmall-cell lung cancer (NSCLC) (1).
William Blackstock +4 more
openaire +2 more sources
Taxanes in combined modality therapy for solid tumors
Critical Reviews in Oncology/Hematology, 2001The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents.
openaire +4 more sources
Combined modality therapy for esophageal cancer
Seminars in Radiation Oncology, 1997Esophageal cancer remains one of the deadliest gastrointestinal malignancies. Single modality therapy for esophageal cancer usually consists of surgery or radiation therapy. Despite wide ranges in survival rates reported for the two modalities, recent analyses suggest that each offers a 5-year survival of approximately 6%.
Hak Choy +2 more
openaire +2 more sources
Postoperative Adjuvant Combined Modality Therapy
2001Significant advances have been made in the adjuvant management of resectable rectal cancer during the 1990s. In patients with clinically resectable disease, pelvic radiation therapy decreases local recurrence. The addition of systemic chemotherapy further decreases local recurrence and improves survival.
C. H. Kohne, Bruce D. Minsky, C. Greco
openaire +2 more sources
The Necessity for Combined Modalities in Cancer Therapy
Hospital Practice, 1973Evidence is abundant that cure of cancer cannot be consistently achieved by a single modality and that the goal of destruction of every cancer cell can be attained only by immunotherapy. But this technique is effective against only a relatively small tumor-cell burden.
openaire +2 more sources
Cancer of the Gastroesophageal Junction: Combined Modality Therapy
Surgical Oncology Clinics of North America, 2006Esophageal cancer, an uncommon, but highly virulent malignancy in the United States, will be responsible for nearly 14,000 deaths in the year 2005. The prognosis for patients who have adenocarcinoma of the distal esophagus and gastroesophageal junction and who are treated with the standard approaches of surgery or combined chemoradiation therapy is ...
openaire +3 more sources
Adjuvant combined modality therapy for malignant meningiomas
Journal of Neurosurgery, 1996✓ Malignant meningiomas constitute 10% to 15% of all meningiomas and limited information exists regarding adjuvant treatment of these aggressive primary brain tumors. Fourteen patients (eight men, six women), ranging in age from 28 to 61 years (median 51 years), were prospectively treated for primary malignant meningiomas according to an institutional ...
openaire +3 more sources
Combined Modality Therapy in Cancer Management
2010The last 30 years have ushered in a convincing argument that combining chemotherapeutic drugs, with actions against specific aspects of the cancer cell cycle or DNA, with ionizing radiation results in clinically meaningful improvements in locoregional control and survival in many epithelial cancers and gliomas.
Kyle E. Rusthoven, David Raben
openaire +2 more sources